That was last week, but I had no time to listen until now - check out the podcast (in the upper left corner of the page):
In 1989, Dr. Harold Varmus won a Nobel Prize for his cancer research. He was director of the National Institutes of Health during the Clinton administration, and now heads the Memorial Sloan-Kettering Cancer Center. Recently, President Obama named him to co-chair his Council of Advisers on Science and Technology. And he's written a new book, "The Art and Politics of Science." In this segment, Ira talks with Harold Varmus about his work, biological research, and the intersection between politics and science.
- Log in to post comments
in addition to 'art' and 'politics' of science, there is 'greed' and 'disingenuousness'; for a summary of ethics and safety concerns at a high profile cancer research center (mskcc), please see: www.mskccheats.blogspot.com; âSloan is pursuing a systemic approach to reducing expenses and increasing revenues [â¦] One example of this is discouraging terminally ill patients from seeking initial treatment or second opinions from the cancer center [â¦] the admission of such patients is counterproductive [â¦] to Sloan Kettering.â [paraphrasing salient features, MSKCC, CFO/Chief Financial Officer]; mskcc, we hoped you'd be our hero. Minimally, you're SUPPOSED to care. Who would build a laboratory building and knowingly NOT install ductwork controls? MSKCC did. Who would terminate under false pretense employees who rightfully complain about safety/health factors only to have to abandon a building for safety/health factors (carbon monoxide exposure to employees)? MSKCC did! Ed Mahoney currently heads mskcc facilities. Attorney Shelly Friedman represents mskcc when it attempts to assuage rightfully concerned community members relative to environmental health and safety issues concomitant with expansion. Why would a non-clinician instruct a coworker to mislead (embargo) known information as to the availability of a clinical trial candidate at mskcc, created by a competitor, when the in house version of the drug had not yet made it out of the proverbial clinical trial gate? Sarah Danishefsky of mskcc did. Boo. You know better.